| Trial ID: | L5056 |
| Source ID: | NCT00230464
|
| Associated Drug: |
Laf 237
|
| Title: |
Acute Metabolic Effects of LAF 237 in Type 2 Diabetics
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: LAF 237
|
| Outcome Measures: |
Primary: Rate of appearance of endogenous glucose | Secondary: Rate of dissapearance of glucose|Fasting glucose|Insulin secretion|Free fatty acids|Glucagon|Rate of appearance of oral glucose
|
| Sponsor/Collaborators: |
Sponsor: The University of Texas Health Science Center at San Antonio | Collaborators: Novartis
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
16
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2004-11
|
| Completion Date: |
2005-09
|
| Results First Posted: |
|
| Last Update Posted: |
2006-01-04
|
| Locations: |
Audie L Murphy VA Hospital, San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00230464
|
